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Abstract T cells with speciﬁcity for antigens derived
from Wilms Tumor gene (WT1), Proteinase3 (Pr3), and
mucin1 (MUC1) have been demonstrated to lyse acute
myeloid leukemia (AML) blasts and multiple-myeloma
(MM) cells, and strategies to enhance or induce such
tumor-speciﬁc T cells by vaccination are currently being
explored in multiple clinical trials. To test safety and
immunogenicity of a vaccine composed of WT1-, Pr3-, and
MUC1-derived Class I-restricted peptides and the pan
HLA-DR T helper cell epitope (PADRE) or MUC1-helper
epitopes in combination with CpG7909 and Montanide-
ISA51, four patients with AML and ﬁve with MM were
repetitively vaccinated. No clinical responses were
observed. Neither pre-existing nor naive WT1-/Pr3-/
MUC1-speciﬁc CD8
? T cells expanded in vivo by vacci-
nation. In contrast, a signiﬁcant decline in vaccine-speciﬁc
CD8
? T cells was observed. An increase in PADRE-spe-
ciﬁc CD4
? T helper cells was observed after vaccination
but these appeared unable to produce IL2, and CD4
? T
cells with a regulatory phenotype increased. Taken into
considerations that multiple clinical trials with identical
antigens but different adjuvants induced vaccine-speciﬁc T
cell responses, our data caution that a vaccination with
leukemia-associated antigens can be detrimental when
combined with MontanideISA51 and CpG7909. Reﬂecting
the time-consuming efforts of clinical trials and the
fact that 1/3 of ongoing peptide vaccination trails use CpG
and/or Montanide, our data need to be taken into
consideration.
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Several lines of investigation have provided conclusive
evidence that epitopes derived from Wilms Tumor1 (WT1)
and Proteinase3 (Pr3) are presented in the context of major
histocompatibility complex (MHC) class I epitopes on
solid cancer cells and/or leukemic blasts, and are poten-
tially immunogenic. Molldrem et al. [1] identiﬁed
Pr3169–177, a nine-amino acid self-peptide derived from Pr3
that binds HLA-A*0201 as a leukemia-associated CD8
? T
cell antigen. Pr3169–177-speciﬁc CD8
? T cells have been
isolated from healthy donors and from patients with
chronic myeloid leukemia (CML), shown to kill CML and
acute myeloid leukemia (AML) cells but not normal
hematopoietic progenitors expressing low levels of these
antigens, and to effectively inhibit the outgrowth of a panel
of CML progenitors in proportion to the level of Pr3 over-
expression [2]. WT1-derived HLA-A*0201-presented epi-
topes, including the HLA-A*0201-presented epitope
WT1126–134, have been shown to elicit epitope-speciﬁc
CD8
? T cells from healthy controls that can lyse myeloid
leukemic blasts [3–5]. Recent clinical studies suggest that
vaccination of patients with either the HLA-A*2402-pre-
sented natural or modiﬁed epitope WT1235–241 [6], the
HLA-A*0201-presented epitope WT1126–134 alone [7], or a
combination of WT1126–134 with Pr3169–177 [8] can indeed
induce leukemia-reactive CD8
? T cells that may contribute
to control of solid tumor cells or leukemic blasts and
induce clinical responses.
Another candidate tumor antigen is the mucin 1 protein
(MUC1). Due to the aberrant glycosylation in the variable
number of tandem repeat (VNTR) domain of MUC1-
protein in cancer cells, non-glycosylated VNTR-derived
peptides (MUC1138–178) have been described as helper
epitopes for the stimulation of CD4
? T cells [9]. VNTR-
derived peptides have been also described as targets for
CD8
? T cells, although these peptides appear unusual in
not fully matching deﬁned binding motifs for the
respective HLA-molecules [10]. Preclinical studies have
also identiﬁed multiple HLA-A*0201 epitopes derived
from regions of MUC1 outside the VNTR including
MUC179–87 [11]. MUC1-derived peptides have been
shown to be presented not only by solid cancers [11], but
also hematological malignancies including MM [12].
Initial clinical vaccination trials in patients with breast or
ovarian cancer [11, 13] conﬁrmed immunogenicity and
lack of toxicity following vaccination with MUC1-derived
immunogens.
In summary, WT1, Pr3, and MUC1-containing vaccines
represent candidates for further clinical evaluation in
patients with AML or MM. Therefore, we tested whether a
vaccine composed of WT1 and Pr3 or MUC1-derived
peptides can induce immunological and clinical responses.
Materials and methods
Clinical protocol
This was a non-randomized, non-blinded, controlled,
bi-centric, open-label, adjuvant vaccination pilot study. Nine
patientsHLA*A0201bygenotypingwereincluded.Inclusion
criteria included conﬁrmed primary or secondary AML or
relapse of an AML, including RAEB/RAEB-T, IPSS score
C1.5; and minimal residual disease (MRD) (deﬁned as[5%
B30% leukemic blasts in bone morrow). Patients with con-
ﬁrmed MM were also eligible if presenting with stage I or
stable disease, or partial remission after cytoreductive che-
motherapy.Furtherinclusioncriteriawerepatientswitholder
than (C) 18 years of age of either gender and of any race, life
expectancy of at least 4 months, and adequate performance
status (Karnofsky score C70%). Systemic corticosteroid or
other immunosuppressive therapies were not allowed within
the last 3 months or during the study. Prior chemotherapy or
radiation therapy was allowed if at least 2 weeks had elapsed
between the last dose of therapy and study entry and the
patient had recovered from all treatment-related toxicities.
Study reagents were injected subcutaneously on days 0, 14,
28,42,56,and70.Patientswerevaccinatedsimultaneouslyat
different locations withtwodifferenttypes ofvaccines.AML
patientsreceivedacombinationofpanHLA-DRThelpercell
epitope (PADRE), CpG7909, MontanideISA51 and either
WT1126–134 (vaccine A) or Pr3169–177 (vaccine B). MM
patients received CpG7909, MontanideISA51, and either
MUC179–87 and PADRE (vaccine C) or the oligomer
MUC1138–178(vaccineD)(Fig. 1).TheoligomerinvaccineD
served as source for CD4
? and CD8
? T cell epitopes. Every
patient received the study substances in a dose of 1.0 mg for
eachpeptide,comparable todoselevelsinother clinicaltrials
[14–16], CpG7909 was administered at a ﬁnal dose of 1 mg,
again within the dose range of other successful clinical vac-
cination trials (range 0.5–8 mg) [17–21]. The ﬁnal vaccine
was freshly prepared from different compounds for each day
of vaccination. PBMCs were collected at day -7( r a n g ed a y
-13/0) and every second week until day 84. Leukapheresis
was performedatday 42(range day 42/56)and 84(rangeday
84/94) in order to harvest PBMCs and collected material
processed and frozen immediately. The study was approved
by the local ethics board, regulatory authorities and has been
registered at the ‘‘Deutsche Krebstudienregister’’ (DKSR
number 415 and 416; http://www.studien.de/includes/
studien_suchen/studie.suchen.php?PIC_CASE=1&L).
Vaccine, peptides, pentamers, and antibodies
Clinical grade peptides were purchased from Clinalfa-
Bachem (Weil am Rhein, Germany), and MontanideISA51
from Seppic (Ko ¨ln, Germany). CpG7909 (VaxImmune
TM)
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123was kindly provided by Coley pharmaceuticals GmbH
(Du ¨sseldorf, Germany). Peptides WT1126–134, PR3169–177,
MUC179–87, HIV-reverse transcriptase: HIVRT 476–484,
HBVcore128–140, and CMVpp65495–504, overlapping
15-mers for MUC1138–178, PADRE, PE-labeled HLA-
A*0201-presented WT1126–134, PR3169–177,M U C 1 79–87,
HIVRT 476–484, and CMVpp65495–504 pentamers were
from ProImmune (Oxford, UK). Anti-CD3-Paciﬁc Blue,
anti-CD4-APC Alexa Fluor 750, anti-CCR7-PE-cy7,
anti-CD27-APC Alexa Fluor 750, anti-PD-1-APC, anti-
FoxP3-APC (including anti-human Foxp3 Staining Set),
anti-TNFa-PE Cy7, anti-IL4-PE Cy7, anti-IL10-PE, were
obtained from Invitrogen (Paisley, UK); anti-CD8-PercP,
CD86-PE, anti-CD25-FITC, anti-CD127-PE Cy7, anti-
IFNc-FITC, and anti-IL2-APC from BD Biosciences
(Erembodegem, Belgium); and anti-CD303-FITC (BDCA-
2) from Miltenyi Biotec (Gladbach, Germany). Flow
cytometry was performed on an LSR II ﬂow cytometer (BD
Biosciences) using FacsDiva software (BD Biosciences).
Pentamer staining and functional T cell assays
Pentamer staining and functional T cell assays were per-
formed as described recently [4, 5, 22–24]. In brief,
*1 9 10
6 PBMCs were incubated with pentamer for
30 min, then directly conjugated antibodies were added for
20 min at 4C in order to specify T cell phenotype (CD3-
Paciﬁc Blue, CD27-APC-Alexaﬂuo 750, PD-1 APC, and
CD8-PercP, CCR7-PE-cy7). Cells were washed with PBS
and resuspended in FACS buffer (0.1% BSA ? 0.1% Na-
azide in PBS) for FACS analysis. Gating for all pentamer
stainings were standardized within individual samples to
arrive at a fully comparative datasets. In order to test
background staining for individual pentamers, 10
6 PBMCs
derived from ﬁve HLA-A*0201-positive but CMV- and
HIV-negative healthy individuals were co-incubated with
individual pentamers and an anti-CD8 antibody and ana-
lyzed by ﬂow cytometry. Unspeciﬁc staining was thereby
determined for all pentamers as B0.05% of CD8
? T cells
Fig. 1 a Vaccine composition,
b patient characteristics, and
clinical responses after
vaccination. CTCAE grading of
side effects is indicated. Clinical
responses were evaluated at the
end of study (day 84). DTH
delayed type hypersensitivity
reaction, SD stable disease, PD
progressive disease, n.d. not
determined, Pretreatment
treatment prior study entry
Cancer Immunol Immunother (2011) 60:161–171 163
123(data not shown). To assess the sensitivity of pentamer
staining to detect vaccine-reactive T cells with intermedi-
ate avidity and low frequency, we took advantage of pre-
vious work from our laboratory with intermediate avidity
WT1126–134-speciﬁc T cells [4, 23]. These data and titration
of a WT1126–134-speciﬁc T cell clone into 10
6 CD8
? T cells
(Supplementary Fig. 4) demonstrate a highly reproducible
and speciﬁc pentamer staining for intermediate avidity T
cell lines and clones with frequencies C0.10%. Intracel-
lular cytokine (ICC) assay was performed as described
recently [4]. In brief, *1 9 10
6 PBMCs were stimulated
with the indicated peptide (10 lg/ml) and Brefeldin A
(GolgiPlug
TM, BD) (1 ll/ml) for 6 h at 37C. After 6 h,
cells were washed and surface antibodies were added: anti-
CD3-Paciﬁc Blue, anti-CD4-APC Alexa Fluor 750, anti-
CD8-PercP. Cells were incubated for 20 min at 4C and
washed with PBS. Cells were ﬁxed and permeabilized with
lysing and permeabilizing solution (BD FACS
TM). Next,
anti-TNFa-PE Cy7, anti-IFNc-FITC, and anti-IL2-APC or
anti-IL4-PE Cy7 and anti-IL10-PE were added. Gating for
all ICC assays was standardized within individual samples
to arrive at a fully comparative datasets. Thereby, back-
ground signal for TNFa, IFNc, and IL2 cytokine secretion
was tested in 2 HLA-A*0201-positive HIV and CMV-
negative healthy individuals. CD4
?- or CD8
? cytokine-
secreting cells were detected in \0.1% of cells (data not
shown), thus the detection threshold was determined as
0.1%. In vitro expansion assays were performed as
described recently [23]. In brief, 1 9 10
6 PBMCs/sample
were stimulated with 1 lg/ml peptides WT1126–134,
PR3169–177, MUC179–87, overlapping 15-mer MUC1138–164,
overlapping 15-mer MUC1153–178, HIVRT 476–484 or
CMVpp65495–503, together with 50 U/ml IL2 (Chiron,
Emeryville, CA, USA), for 1 week at 37C. After 1 week,
a 6-h stimulation followed by an ICC assay was performed
as described above. T cell clones with speciﬁcity for
WT1126–134 have been generated as described recently [4,
5, 23]. A twofold change in frequency of antigen-speciﬁc T
cells was considered as vaccine-induced, an arbitrary
threshold used in multiple vaccination studies to deﬁne
vaccine-speciﬁc immune responses [7, 8].
Results
Study design and patient characteristics
The study was designed to induce leukemia-/MM-reactive
T cells with a polyvalent vaccine composed of HLA-
A*0201-presented peptides WT1126–134 (vaccine A) and
Pr3169–177 (vaccine B) (AML patients) or MUC179–87
(vaccine C) and those derived from MUC1138–178 (vaccine
D) (MM patients) (Fig. 1). The vaccine included either a
PADRE, which was engineered to bind common HLA-DR
molecules with high afﬁnity [25, 26], or a MUC1 oligomer
[9] to induce CD4
? helper T cells. To enhance immuno-
genic antigen-presentation, CpG7909 (VaxImmune
TM), a
single-stranded oligodeoxynucleotide (ODN) that activates
plasmacytoid dendritic cells through toll-like receptor
(TLR) 9 triggering, and has been reported to increase
tumor-reactive CD8
? T cells upon vaccination in mela-
noma patients [17], was also included. Four AML (vaccine
A ? B) and 5 MM (vaccine C ? D) patients were simul-
taneously vaccinated every 2 weeks until a total of six
vaccinations (Fig. 1).
Clinical outcome and side effects
During the study observation period, two of four AML
patients had progressive disease according to IWG criteria
[27]; two of ﬁve MM patients progressed (EBMT, IBMTR
and ABMTR criteria [28]); and, all other patients had
stable disease at study day 84 (Fig. 1b). As all patients
have not been progressive before vaccination, and also no
late responses were observed, we concluded that no clinical
responses were observed [7]. After vaccination, all patients
had inﬂammation at the injection sites (grades II–III tox-
icity according to CTCAE: Cancer Therapy Evaluation
Program, Common Terminology Criteria for adverse
Events, Version 3.0). Four patients experienced mild fati-
gue (grades I–II) and three had fever (grades I–III)
(Fig. 1b). To assess for vaccine-speciﬁc T cell responses, a
delayed type hypersensitivity (DTH) test was performed
with the following peptides from the vaccine at study
days 2, 44, and 86: PADRE (all patients); WT1126–134,
PR3169–177 (AML patients); and MUC179–87 and
MUC1138–178 (MM patients). None of the patients had a
positive DTH test with any peptide at any time (Fig. 1b).
Vaccine-speciﬁc CD8
? T cells (VST) cannot be
recruited by vaccination and rather decline
To investigate if vaccination of the four AML patients
with the HLA-A*0201-binding peptides WT1126–134,
PR3169–177, or the ﬁve MM patients with the MUC179–87
peptide increased the frequency of VST, collected PBMCs
were incubated with HLA-A*0201 restricted WT1126–134
and PR3169–177 pentamers if vaccinated with vaccines A
and B (4 patients with AML) and MUC179–87 pentamers if
vaccinated with vaccines C and D (5 patients with MM)
[4, 5, 23]. As a negative control, an HIVRT476–484 pentamer
was used; and as a positive control, a CMVpp65495–503
pentamer was used. In six of nine patients, pp65495–503-
speciﬁc T cells were detectable prior to vaccination
and through study day 84 (range 0.15–3.30%) (CMVpos
group) and frequencies did not signiﬁcantly differ when
164 Cancer Immunol Immunother (2011) 60:161–171
123comparing patients before and after vaccination (Fig. 2a).
Four of ﬁve MM patients had pre-existing MUC179–87
pentamer-positive CD8
? T cells (range 0.15–0.30%) and
one AML patient had pre-existing WT1126–134 pentamer-
positive CD8
? T cells (0.15%, Supplementary Fig. 1)
(deﬁned as VST group). Thus, four patients had no VST
prior vaccination (NoVST group). When comparing the
frequency of VST in the group of patients with NoVST
before and after vaccination, no increase in VST was
observed. In contrast, a slight but signiﬁcant decline in
pentamer-positive VST (AML and MM patients, p = 0.02)
was observed within the VST group (n = 5 patients) after
vaccination while the frequency of pp65495–503-speciﬁc T
cells did not change signiﬁcantly (Fig. 2a), e.g., in patient 4
with pre-existing WT1126–134 pentamer-positive CD8
? T
cells (0.15%) the WT1126–134 pentamer-positive CD8
? T
cells were no longer detectable at all other time points after
vaccination including days 42 and 84 (Fig. 2a, Supple-
mentary Fig. 1). In addition, no VST were observed in the
bone marrow of patients before or 84 days after vaccina-
tion (data not shown).
To assess if the phenotype of persisting pentamer-posi-
tive CD8
? T cells changed from naı ¨ve/central memory
(CD27
?/CCR7
?) to effector memory/effector (CD27
-/
CCR7
-) after vaccination, CD8
? T cells were stained with
pentamer, anti-CD27 and anti-CCR7 at day -7 and 42.
Percentage of CD27
-/CCR7
- pentamer-positive T cells
was compared before and after vaccination and indeed only
for MUC179–87 but not for pp65495–503 pentamer-positive T
cells a signiﬁcant increase (t test p = 0.03) in the CD27
-/
CCR7
-cell population was observed suggesting that naı ¨ve/
central memory cells indeed had become effector memory
or effector cells after vaccination (Fig. 2b). However, VST
apparently failed to proliferate and were rather depleted
(Fig. 2a). The pentamer-positive cells were also stained
with anti-PD1, a marker of T cell exhaustion [29], but none
of the pentamer-positive cells exhibited substantial PD1-
expression (data not shown).
WT1- and MUC1-speciﬁc CD8
? T cells
are functionally impaired
The failure of pre-existing pentamer-positive WT1- and
MUC1-speciﬁc T cells to expand after vaccination could be
either a consequence of complete anergy, with an absolute
inability to respond to antigen, or a selective inability to
proliferate [30]. Therefore, PBMCs of patients within the
VST group were stimulated for 6 h with WT1126–134 and
PR3169–177 peptides (AML patients) and MUC179–87 pep-
tide and overlapping 15-mers derived from the
MUC1138–178 oligomer (MM patients). Although, all tested
patients had pre-existing WT1126–134 or MUC179–87 pen-
tamer-positive cells (Fig. 2a, b), we failed to detect speciﬁc
TNFa, IFNc, o rIL2 production by ICC in response
to respective antigens before and after vaccination
(all \0.1%), suggesting that the detectable WT1-/MUC1-
pentamer-positive CD8
? T cells were not functional in
vivo prior to vaccination, and that function could not be
rescued by vaccination. Also 7 days of stimulation of
PBMCs from selected patients with MUC179–87, and two
pools of overlapping 15-mers derived from MUC1138–164
and MUC1153–178 (MM patient), pp65495–503, and HIVRT
476–484, did neither result in any pentamer-positive
(\0.05%, data not shown) nor functional VST (Table 1)
after vaccination, while pp65495–503-speciﬁc T cells did not
change in frequency (Table 1). Only in one AML patient
(patient 1) who had no pre-existing vaccine-reactive T cells
by pentamer staining, we could generate 0.4% CD8
? T
cells with speciﬁc IFNc production against WT1126–134
prior to vaccination which were, however, no longer
detectable after vaccination (Table 1; Supplementary
Fig. 2) in line with the observation that vaccination
decreased the number of pentamer-positive VST (Fig. 2a).
Expansion of PADRE-speciﬁc CD4
? T helper cells
which do not substantially produce IL2
All vaccines contained a potential CD4
? T helper epitope,
either the ‘pan HLA-DR T helper epitope’ PADRE or
MUC1138–178, to induce CD4
? T helper cells and poten-
tially improve the generation and persistence of WT1-/
Pr3-/MUC1-speciﬁc CD8
? T cells. In ﬁve of eight
patients, PADRE-speciﬁc CD4
? T cells were detected
prior to vaccination (range 0.20–0.40% of CD4
? T cells)
that produced either IFNc or TNFa, but no IL2, IL4, or
IL10 production was detectable (Fig. 2c and data not
shown for IL4 and IL10). A signiﬁcant increase in IFNc-
producing PADRE-speciﬁc CD4
? T cell responses was
detected after vaccination. Also higher amounts of TNFa-
producing PADRE-speciﬁc T cells were observed,
although not signiﬁcant. T cells did not produce IL2
(Fig. 2c). In Patient 7, a two- to fourfold induction of
TNFa producing MUC1153–178-speciﬁc CD4
? T cells was
observed (\0.1% day -7, 0.4% day 42, 0.2% day 84),
and, again, no IL2 production could be measured (Sup-
plementary Table 1).
In order to test more thoroughly if PADRE stimulation
could lead to induction of IFNc and TNFa-secreting CD4
?
T cells that lack the ability to produce detectable amounts
of IL2, PBMCs were stimulated for 1 week with helper
peptides. In all four patients, PADRE-speciﬁc T cells were
detectable prior to vaccination (frequency 0.2–2.0%) by
ICC and produced either IFNc or both IFNc and TNFa.
More importantly, in two patients they also produced IL2
(Table 2). After vaccination, the frequency of IFNc- and/or
TNFa-secreting cells increased twofold until day 42 or 84
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Supplementary Fig. 3). Although the number of PADRE-
speciﬁc IFNc and/or TNFa producing CD4
? T cells
increased substantially after vaccination in all patients, pre-
existing IL2 producing PADRE-speciﬁc CD4
? T cells in
patients were not found in greater numbers (Table 2).
Fig. 2 Decrease in vaccine-
speciﬁc T cells (VST) and
increase in regulatory CD4
? T
cells after vaccination.
a Pentamer-positive CD8
? T
cells before (day -7) and after
(days 14–84) vaccination in all
patients (n = 9). CMV sero-
positive (CMVpos) group
n = 6, sero-negative (CMVneg)
group n = 3, VST before
vaccination group (VST) n = 5,
no VST before vaccination
group (NoVST) n = 4, HIV-
reverse-transcriptase-peptide
(HIVRT). b Pentamer-positive
CD8
? T cells were gated and
percentages of pentamer-
positive effector memory/
effector T cells (CD27
-/
CCR7
-) calculated before
vaccination and at day 42 after
vaccination. c Percent cytokine
producing PADRE-speciﬁc
CD4
? T cells as measured by
ICC. d Flow cytometry analysis
of patient-derived PBMC
samples collected prior to
vaccination and at day 42 and
84. Cells were incubated with
anti-CD3, anti-CD8, anti-CD4,
anti-CD25, anti-CD127, and
anti-FoxP3. Regulatory
phenotype is deﬁned as:
CD25
?CD127
lowFoxP3
? CD4
?
T cells. The dotted line
represents the threshold of a
more then twofold increase of
CD25
?CD127
lowFoxP3
? CD4
?
T cells after vaccination. n.p.
not possible
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123Thus, IL2 production appeared to be impaired in PADRE-
speciﬁc CD4
? T cells after vaccination.
Increase of CD4
? T cells with a regulatory phenotype
after vaccination
It has been reported that CpG7909 can stimulate plas-
macytoid dendritic cells and thereby increase the number
of CD4
? T cells with a regulatory phenotype and func-
tion in vitro [31] and in vivo [32] in mice, which could
consequently inhibit the success of a vaccine [32, 33]. To
investigate if the vaccination regimen inﬂuenced the
frequency or maturation of plasmacytoid dendritic cells
as reported recently (deﬁned as CD303- and CD86-
positive [21, 34]) or the frequency of regulatory T cells
in the peripheral blood, patient-derived PBMC obtained
at day -7, 42, and 84 were stained with anti-CD303
(BDCA-2) antibody, a single marker for plasmacytoid
dendritic cells [35], anti-CD86, anti-CD25, anti-FoxP3,
and anti-CD127, and analyzed by ﬂow cytometry. The
amount of both, immature (CD86
-) and mature (CD86
?)
anti-CD303-positive (plasmacytoid dendritic) cells did
not increase more then twofold over 84 days (range
plasmacytoid dendritic cells \0.1–0.4% of total PBMCs)
(Supplementary Table 2). However, ﬁve out of eight
patients showed a more than twofold increase in CD25
?
FoxP3
? CD127
low CD4
? T cells in one or both time
points after vaccination (range 2.4–6.0-fold increase)
(Fig. 2d).
Discussion
The main ﬁndings of our studies are that in contrast to
multiple other vaccination phase I studies using similar
antigens [7, 8, 11, 13, 36, 37] pre-existing WT1-/MUC1-
speciﬁc T cells in advanced stage cancer patients (a) nei-
ther proliferated nor secreted cytokines upon peptide
stimulation and (b) were rather depleted than rescued after
vaccination.
Table 1 Cytokine production of in vitro expanded leukemia-/MM-/virus-speciﬁc CD8
? T cells before and after vaccination
After 7 days in vitro re-stimulation of CD8
? T cells
Peptide HIVRT476–134 pp65495–503 WT1126–134 Pr3169–177
Day -74 2 & 8 4 -74 2 & 8 4 -74 2 & 8 4 -74 2 & 8 4
1 IFNg \0.1 \0.1 24.6 22.3
a 0.4 \0.1 \0.1 \0.1
a
TNFa \0.1 \0.1 4.0 3.9
a \0.1 \0.1 \0.1 \0.1
a
IL2 \0.1 \0.1 0.4 0.2
a \0.1 \0.1 \0.1 \0.1
a
2 IFNg \0.1 \0.1
a 0.7 0.3
a \0.1 \0.1
a \0.1 \0.1
a
TNFa n.p. \0.1
a n.p. 0.3
a n.p. \0.1
a n.p. \0.1
a
IL2 \0.1 \0.1
a 0.2 \0.1 \0.1 \0.1 \0.1 \0.1
a
3 IFNg \0.1 \0.1
a \0.1 \0.1
a \0.1 \0.1
a \0.1 \0.1
a
TNFa n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d.
IL2 \0.1 \0.1
a \0.1 \0.1
a \0.1 \0.1
a \0.1 \0.1
a
After 7 days in vitro re-stimulation of CD8
? T cells
Peptide HIVRT476–134 pp65495–503 MUC179–87 MUC1153–178
MUC1138–164
Day -74 2 & 8 4 -74 2 & 8 4
9 IFNg \0.1 \0.1 \0.1 \0.1
a \0.1 \0.1 \0.1 \0.1
TNFa \0.1 \0.1 \0.1 \0.1
a \0.1 \0.1 \0.1 \0.1
IL2 \0.1 \0.1 \0.1 \0.1
a \0.1 \0.1 \0.1 \0.1
Pre-existing 0/4 2/4 1/4 0/4
Induction 0/4 0/4 0/4 0/4
Loss 0/4 0/4 1/4 0/4
Intracellular cytokine production (ICC) 7 days after antigen-speciﬁc in vitro stimulation. Bold numbers indicate the speciﬁc detection of
cytokine-secreting CD8
? T cells; italic numbers indicate a twofold change when compared with day -7. If for day 42 & 84 only one value is
indicated then measured values are identical
n.d. not determined due to lack of material
a Only one of the indicated time points was analyzed
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WT1/MUC1-reactive T cells were observed in multiple
patients before but not after vaccination. We also did not
detect vaccine-reactive T cells in the bone marrow, a
preferential homing side of memory T cells [38]. Thus,
vaccination could have induced anergy or exhaustion of
pre-existing VST. Anergy and exhaustion of tumor-reac-
tive T cells in cancer patients can occur either from chronic
or suboptimal antigen stimulation or from other immuno-
suppressive events supported by tumor cells or their
microenvironment [39]. Exhaustion, anergy or deletion of
reactive T cells has also been reported after repetitive
injections of high doses of peptide i.p. [40], after a single
low dose of peptide s.c. [41] or after introduction of anti-
gens to immature dendritic cells through the endocytic
receptor DEC-205 in mice [42].
The differences observed in our clinical study when
compared with other vaccine trials might also reﬂect the
type of underlying disease in vaccine recipients. Regula-
tory mechanisms potentially active in cancer patients that
might be increasingly operative in patients with AML
include myeloid suppressor cells, which can secrete
inhibitory cytokines [43] or depletion of tryptophan by
leukemic blasts [44]. However, recent clinical phase I
studies suggest that vaccination of AML patients with
WT1-derived peptides can induce leukemia-reactive CD8
?
T cells in patients with low and high leukemia load [6–8]
making it unlikely that the type or stage of disease alone
were responsible for the absence of immunogenicity of the
vaccine tested in our study.
Epitope dominance and competition for HLA-class I-
presented antigens on dendritic cells have been suggested
as a mechanism, which can impair immune responses to
certain antigens [45]. However, a successful combined
vaccination with WT1 and Pr3 has been reported [8]
making it unlikely that the combination of antigens ham-
pered the success of our vaccine. Furthermore, HLA-class
I-presented antigens were injected at different sites in order
to circumvent the competition for antigen-loaded dendritic
cells.
Multifunctional T cells are generally required to control
viral infections or tumors [46]. Thus, T cells need to not
only produce effector cytokines, e.g., TNFa, but also other
cytokines such as IL2 that are essential for promoting T
cell proliferation. The inability to detect IL2 production by
PADRE-speciﬁc T helper cells could have impaired the
induction of CD8
? T cells or even supported depletion of
MUC1/WT1-reactive CD8
? T cells. It has indeed been
reported that IL2 production of PADRE-speciﬁc CD4
? T
cells is crucial to induce potent CD8
? T cell responses
[47], and induction of IL2-producing PADRE-speciﬁc T
cells has been selectively achieved when PADRE was
directly loaded onto dendritic cells. This suggests that the
presentation of the delivered helper antigen by professional
antigen-presenting cells was suboptimal in our clinical
trial.
To improve delivery and presentation of tumor antigens,
clinical trials targeting MUC1, WT1 or Pr3 have taken
advantage of peptide-pulsed dendritic cells [11]o r
administration/production of GM-CSF [7, 8, 13], although
other studies have used no additional stimuli [6]. In all
these studies, MHC class I-restricted vaccine-speciﬁc T
cell responses could be enhanced. In our study, the vaccine
contained CpG7909, which can activate plasmacytoid
dendritic cells through TLR9 [48]. Successful vaccination
trials with WT1 have been reported with myeloid dendritic
cells [37] and the difference in the type of dendritic cell
might have indeed hampered the immunological outcome
of our trial. However, CpG7909 has been also reported to
increase Melan-A- or NY-ESO-1-speciﬁc CD8
? T cells in
combination with a peptide vaccine in patients at dose
levels 0.5–2.5 mg, which is comparable to the 1 mg dose
used in our trial [17, 19, 20]. At higher dose levels of
6–8 mg without providing exogenous antigens, CpG7909
has been reported to boost pre-existing CD8
? T cells with
speciﬁcities against various melanoma-associated antigens,
to induce an activated phenotype in plasmacytoid dendritic
cells, and to enhance natural killer cell cytotoxicity [18,
Table 2 Cytokine production of PADRE-speciﬁc CD4
? T cells
before and after vaccination
Day After 7 days of PADRE-speciﬁc ex vivo expansion
-74 2 & 8 4
1 AML IFNc 0.4 2.6 & 0.6
TNFa 0.4 5.7 & 0.8
IL2 \0.1 \0.1
2 AML IFNc 0.4 7.1 & 6.1
TNFa 2.0 9.9 & 9.0
IL2 0.3 0.3 & 0.2
3 AML IFNc 0.2 2.3
a
TNFa n.d. n.d.
IL2 \0.1 \0.1
a
9 MM IFNc 0.4 0.3 & 1.1
TNFa 0.2 0.3 & 1.2
IL2 0.3 0.3 &\0.1
Pre-existing 4/4
Induction 4/4 (TNFa and/or IFNc)
Loss 1/4 (IL2)
PADRE-speciﬁc cytokine production of CD4
? T cells expression was
measured by intracellular cytokine production assay (ICC) 7 days
after PADRE-speciﬁc stimulation. Bold numbers indicate the speciﬁc
detection of cytokine-secreting CD4
? T cells; italic numbers indicate
a twofold change when compared with day -7
n.d. not determined due to lack of material
a Only 1 of the indicated time points was analyzed
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12321]. In our clinical trial, we could not detect an increase in
activated phenotype of plasmacytoid dendritic cells, which
could be a consequence of the lower CpG7909 dose used in
our trial. An insufﬁcient maturation of professional anti-
gen-presenting cells resulted most likely in a suboptimal
antigen-presentation and could thereby explain the
observed partial deletion of pre-existing tumor-speciﬁc T
cells after vaccination [42].
A reduced CD8
? T cell response has also been observed
in mice after vaccination with a TLR9 agonist [49]. We
observed in a similar mouse model that although the
combination of MontanideISA51 and CpG7909 has no
negative impact on humoral immune responses, this com-
bination has in particular with low CpG doses a negative
impact on CD8
? T cell responses (unpublished results RD
Weeratna, A Vicari, HL Davis). Thus, the negative impact
on CD8
? T cell responses observed in the current study
with this adjuvant combination is most likely due to the use
of a low CpG concentration (1 mg when compared with
2.5–8 mg) [17–21] with suboptimal activation of antigen-
presenting cells and a subsequently weakened Th1
response.
Finally, it has also been reported that CpG7909 can
induce regulatory T cells in vitro [31] and that regulatory T
cells can dampen an immune response after vaccination in
men [50]. We did observe in our cohort an increase in T
cells with a regulatory phenotype after vaccination. How-
ever, as three out of ﬁve patients with a twofold increase in
regulatory T cells also had disease progression, we cannot
entirely exclude that the increase in regulatory T cells was
at least partially a consequence of disease progression or
other physiological changes rather than a consequence of
the vaccine [51]. An increase in regulatory T cells has also
been observed in other vaccination trials [52] and a suc-
cessful vaccination in AML or MM patients has been
associated with a decrease in regulatory T cells [53]. Thus,
regardless of the underlying mechanism, the increase in T
cells with a regulatory phenotype might have further
hampered the success of the vaccine, particular in the
context that antigen delivery to professional antigen-pre-
senting cell may have been sub-optimal.
In summary, we demonstrate that in contrast to our
intention vaccination with WT1-, Proteinase3- and MUC1-
derived peptides in combination with MontanideISA51 and
CpG7909 rather hampers CD8
? T cell responses in men.
To our knowledge all so far published phase I studies with
here used antigens [7, 8, 11, 13, 36, 37] included usually
small numbers of patients (10–20) and reported the
induction of VST after vaccination. This might partially
reﬂect a strong bias towards the publication of positive
clinical trials but could also reﬂect differences in the
adjuvant used in our clinical trial. In this context, we
speculate that the composition of the adjuvant can be of
utmost importance for the success of a vaccine, e.g., sub-
optimal concentrations of CpG or combinations of different
adjuvants with well deﬁned immunogenic antigens can be
detrimental, need to be avoided; and recently reported
superior adjuvants [7, 8, 11, 13, 36, 37] should preferen-
tially be used. However, we cannot entirely exclude con-
founding factors, e.g., due to the small sample size and
physiological variations in immunological analyses of
small patient cohorts, which are also a substantial problem
for previously published clinical trials with a positive
outcome. Considering that 1/3 (57 of 147) of ongoing
peptide vaccination trails currently registered at clinical-
trials.gov use Montanide and that an increasing amount of
trials take advantage of CpG or the combination of CpG
and Montanide, our data need to be taken into consider-
ation for the design of ongoing and planned immunother-
apy protocols.
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